YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Quick Read AKTS retains full worldwide rights to its alpha-emitting cancer platform, with $517M cash and binary Q1 2027 trial data looming. NVS, whose Pluvicto grew 43% in Q2 2026, and LLY, already a $60M upfront partner, rank as the top t…
(RTTNews) - Among Friday's notable biotech movers were TherapeuticsMD, which is evaluating a strategic review process; Sensei Biotherapeutics, supported by optimism surrounding a key clinical catalyst expected in the second half of 2026; a…
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including…
Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic castration-resistant pros…
On May 13, 2026, Avidity Partners Management disclosed a new position in Aktis Oncology(NASDAQ:AKTS), acquiring 468,566 shares in the first quarter. The estimated transaction value was $9.10 million based on quarterly average pricing. What…
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, includi…
Aktis Oncology, Inc. (NASDAQ:AKTS) is one of the 8 Healthcare Stocks Insiders Are Buying. On March 31, 2026, H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology, Inc. (NASDAQ:AKTS) to $33 from $30 previous…
(Bloomberg) — MiniMed Group Inc., a diabetes management firm that will be separated from health-care giant Medtronic Plc, is seeking to raise as much as $784 million in an initial public offering. The Northridge, California-based firm plan…
By Atharva Singh and Arasu Kannagi Basil Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasd…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Northland upgraded Palantir (PLTR) to Outp…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Northland upgraded Palantir (PLTR) to Outp…
2025 was a better year for IPOs than 2024. More than 200 companies raised about $33.6 billion, up from 150 companies and roughly $30 billion the year before. Although the tech theme dominated, thanks to the wider AI trade, names from the h…
In the past week, a beneficial owner has continued to build a stake in insurance giant W.R. Berkley Corp. (NYSE: WRB). And public offerings of shares of biotech firms Alumis Inc. (NASDAQ: ALMS) and Aktis Oncology Inc. (NASDAQ: AKTS) also b…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Aktis Oncology (AKTS) has just come through a busy debut, with a US…
AKTIS Oncology logo above a laboratory dish with glowing molecular particles, representing cancer research and drug development. Key Points While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’…
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At Aktis Oncology, a filing with the SEC reve…
This article first appeared on GuruFocus. Aktis Oncology Inc. (NASDAQ:AKTS) drew strong investor demand in its Nasdaq debut, with shares trading at $22.91 as of 12:19 p.m. Friday in New York after pricing its initial public offering at $18…
Vida has partnered with Aktis since co-leading its Series A, supporting the company from discovery through IPO and establishing itself as one of Aktis’ largest shareholders; Helen Kim, Vida Senior Managing Director, has served on the Board…
[Wooden blocks with the word IPO and virtual stock graph. Initial Public Offering or stock launch concept.] fadfebrian Clinical-stage biotech Aktis Oncology (AKTS [https://seekingalpha.com/symbol/AKTS]), which counts Eli Lilly (LLY [https:…
[IPO Initial Public Offering text, inscription. IPO concept, banner. 3D render] bin kontan * Aktis Oncology (AKTS [https://seekingalpha.com/symbol/AKTS]) priced [https://seekingalpha.com/pr/20358916-aktis-oncology-announces-pricing-of-its-…
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Radiopharmaceutical drug developer Aktis Oncology on Thursday said it raised $318million from…
The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech first revealed plans for an IPO in mid-De…
[IPO Buzzword Cubes - 3D Rendering] porcorex/iStock via Getty Images Aktis Oncology (AKTS [https://seekingalpha.com/symbol/AKTS]), a radiopharmaceutical drug developer that counts Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) among…
Investing.com -- Aktis Oncology Inc., a clinical-stage biotechnology company developing radiopharmaceuticals for cancer treatment, plans to raise up to $212 million in its upcoming U.S. initial public offering. The Boston-based company fil…
Steer clear of stocks to avoid in order to effectively protect your investment portfolio. Moreover, the essence of investing is identifying the next high-flying stock and knowing which stocks to avoid. Additionally, in the past year, we’ve…
Revenue: $7.5 million, up 7% sequentially. Operating Loss (GAAP): $22.6 million. Net Loss Per Share (GAAP): $0.26. Operating Loss (Non-GAAP): $12.5 million. Net Loss Per Share (Non-GAAP): $0.14. Capital Expenditures: $0.3 million. Cash Use…
While investors shouldn’t get too focused on any one signal, a great source of confidence stems from insider favorite stocks. As the old adage goes, it’s difficult to tell what insider selling means. After all, investors could exit a posit…
Akoustis, Inc. Charlotte, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters f…
Akoustis, Inc. First BAW Design Win at a Tier-1 Automotive Customer in the Fast-Growing EV Market Segment Based on IC Reference Design by a Leading Semiconductor Supplier Production Expected to Ramp in the March Quarter of Calendar Year 20…
Akoustis, Inc. Board Co-Chair, CEO, CPO, and Other Company Management and Employees Investing $1 Million Charlotte, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integr…
Akoustis, Inc. Charlotte, N.C., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters f…
Akoustis, Inc. Second Tier-1 Customer to Use Multiple Akoustis 5 GHz and 6 GHz Wi-Fi 7 Filters for a 4X4 MU-MIMO AP Platform Has Received Prototype Orders to Enable Production Ramp in the Second Half Calendar Year 2024 Charlotte, N.C., Jan…
Akoustis, Inc. Charlotte, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters f…
Akoustis, Inc. Charlotte, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters f…
Akoustis, Inc. Charlotte, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters f…